問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Surgery

Division of General Internal Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

鍾為邦Chung, Wei-Pang
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

  • edgarbun@gmail.com

Recruiting Trial

127Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鍾為邦

List

258Cases

2020-12-01 - 2028-12-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2018-09-26 - 2022-05-18

Phase III

Active
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

  • Condition/Disease

    Unresectable Locally Advanced Urothelial Cancer Metastatic Urothelial Cancer

  • Test Drug

    Durvalumab (MEDI4736)/TREMELIMUMAB

Participate Sites
7Sites

Recruiting6Sites

蘇柏榮
Linkou Chang Gung Medical Foundation

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2018-06-15 - 2021-06-30

Phase III

Completed
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Ureteral Cancer Urothelial Cancer Bladder Cancer

  • Test Drug

    Enfortumab Vedotin (ASG-22CE)

Participate Sites
6Sites

Recruiting6Sites

林永昌
Linkou Chang Gung Medical Foundation

2017-11-01 - 2020-03-19

Phase II/III

Completed
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC)and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2018-08-01 - 2032-07-01

Phase III

Active
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS ≧ 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    RO5424802(Alectinib)、capsule、 150mg

Participate Sites
9Sites

Recruiting8Sites

2022-02-01 - 2022-04-06

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2022-06-01 - 2032-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2022-10-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

2023-01-01 - 2028-11-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

1 2 3 4 5 26
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB